{"id":765127,"date":"2023-06-21T09:19:31","date_gmt":"2023-06-21T13:19:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/"},"modified":"2023-06-21T09:19:31","modified_gmt":"2023-06-21T13:19:31","slug":"silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/","title":{"rendered":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent"},"content":{"rendered":"<h2>\nNew patent expands Company\u2019s intellectual property and technology rights portfolio<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>ENGLEWOOD CLIFFS, NJ, June  21, 2023  (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc.\u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16\/825,371 titled \u201cPeptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.\u201d The new patent claims cover the Company\u2019s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.<\/p>\n<p>Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, \u201cOur SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and\/or nanoparticles to study arthritic pathogenesis. The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication.\u201d <\/p>\n<p>An estimated 1.3 million U.S. adults suffer from RA, the most common autoimmune disease in U.S. The U.S. market for RA drugs is expected to generate $63 billion by 2027.<sup>1<\/sup><\/p>\n<p>\n        <strong>About Silo Pharma\u00a0<\/strong>\n      <\/p>\n<p>Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer\u2019s disease, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n7Xps7YPwHPfXrd8fpuYX4qOdDheGEyYIVgIRfqHRyQVsDVyhFtuqW5R6tRT1m0jAmFudlyWsAdiTjMUddfY5t6rrjOTw9nBkIAwKMQq5oQ=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.silopharma.com<\/u><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements\u00a0<\/strong>\n      <\/p>\n<p>All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is\/are likely to&#8221; or other similar expressions. The Company under takes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company&#8217;s filings with the SEC.<\/p>\n<p>\n        <strong>Contact\u00a0<\/strong>\n      <\/p>\n<p>800-705-0120\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WwtXMU7aLB2Y4CUc44i41BVmvs7diQRuZIqRIs1eNE7dzI6gnTKBICkyVzczDCDkgDplI_l0a6nMAMCKEJF5nSDXmUiulCk662Z4g0p5yLw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors@silopharma.com<\/u><\/a><\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup><br \/>\n        <em>Allied Market Research, October 2020<\/em>\n      <\/p>\n<p>\n        \n      <\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjgyZTIwZjktYmU3OC00MzYzLTgzOWItOWE5ZjEzNTM1YTFlLTUwMDA2OTMzOQ==\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New patent expands Company\u2019s intellectual property and technology rights portfolio ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc.\u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16\/825,371 titled \u201cPeptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.\u201d The new patent claims cover the Company\u2019s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, \u201cOur SPU-21 liposomal homing peptides, licensed from the University &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765127","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New patent expands Company\u2019s intellectual property and technology rights portfolio ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc.\u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16\/825,371 titled \u201cPeptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.\u201d The new patent claims cover the Company\u2019s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, \u201cOur SPU-21 liposomal homing peptides, licensed from the University &hellip; Continue reading &quot;Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-21T13:19:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent\",\"datePublished\":\"2023-06-21T13:19:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/\",\"name\":\"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\",\"datePublished\":\"2023-06-21T13:19:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk","og_description":"New patent expands Company\u2019s intellectual property and technology rights portfolio ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc.\u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16\/825,371 titled \u201cPeptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.\u201d The new patent claims cover the Company\u2019s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, \u201cOur SPU-21 liposomal homing peptides, licensed from the University &hellip; Continue reading \"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-21T13:19:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent","datePublished":"2023-06-21T13:19:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/"},"wordCount":483,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/","name":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==","datePublished":"2023-06-21T13:19:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTY5MiM1NjU3MDkzIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma\u2019s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765127"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765127\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}